Notably, PPARα- and gut-liver axis-related processes, and metabolically active myeloid cell infiltration indicate intervention-related mechanisms supporting the indication of SG for the treatment of MASLD. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.